Opinion|Videos|January 29, 2025

BCG-Unresponsive NMIBC and Treatments

Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options include cystectomy, intravesical chemotherapy, immunotherapy, or clinical trials.

Episodes in this series

2 experts in this video

EP. 1 Standard of Care in NMIBC

2 experts in this video

EP. 2 BCG-Unresponsive NMIBC and Treatments

2 experts in this video

EP. 3 Recent FDA Approvals in NMIBC

2 experts in this video

EP. 4 Selecting Treatment for BCG-Unresponsive NMIBC

2 experts in this video

EP. 5 BOND-003 Trial and Cretostimogene for Treatment of NMIBC

2 experts in this video

EP. 6 Other Emerging Intravesical Therapies in NMIBC

2 experts in this video

EP. 7 Emerging Immunotherapies in NMIBC

2 experts in this video

EP. 8 Future of BCG in NMIBC

Video content above is prompted by the following:

When do you consider a patient to have BCG-unresponsive disease?
What treatment options are available for BCG-unresponsiveness/intolerance in patients?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

ByNima Almassi, MD

August 13th 2026

Managing AKT Inhibitor Adverse Events in mHSPC

ByScott Sellinger, MD, FACS

August 13th 2026

Blue light cystoscopy is tied to higher resource use, not health care cost, in NMIBC

ByHannah Clarke

August 11th 2026

Contextualizing Cretostimogene in the Evolving Treatment Landscape

ByMark D. Tyson, MD, MPH

August 10th 2026

Safety, Tolerability, and Practice Integration of Cretostimogene

ByMark D. Tyson, MD, MPH

August 10th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC

Focal therapy for prostate cancer frequently used outside guideline-supported groups

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

Published LITESPARK-011 data show PFS benefit with belzutifan plus lenvatinib in ccRCC

Registry launches to assess real-world clinical utility of ArteraAI Prostate Test